BOSTON SCIENTIFIC CORP

Boston Scientific’s strategic acquisitions fuse diagnostics with cell‑therapy delivery, boosting safety, efficacy, and workflow efficiency in the evolving biologics market.

Boston Scientific’s revised target price shows a cautious outlook amid slowing growth, but its strategic acquisitions in a consolidating medical‑device market signal hidden upside and resilience.

Boston Scientific’s new 14 M incentive options boost capital while aligning staff, shareholders and patient outcomes, fueling R&D and value‑based reimbursement success.

Boston Scientific’s Watchman device faces slower growth, prompting a revised price target, but strong safety, efficacy and a diversified portfolio keep the “buy” rating intact.

Boston Scientific’s recent Form 4 filing shows CEO Mahoney’s ownership shift, yet the company’s solid cash flow, R&D focus on AI/digital health, and resilience to Medicare‑reimbursement changes keep it poised for growth in the competitive medical‑de…

Boston Scientific’s latest Form 4 filing reveals CEO Michael Mahoney’s direct share transfer to his trust—insider transparency, no operational impact.

Boston Scientific’s inclusion in SPY’s record‑high rally highlights its strong AI‑enabled medical devices, low safety risk, and robust regulatory strategy, boosting investor confidence and patient outcomes.

Boston Scientific’s FRACTURE trial proves its IVL catheter is safe and effective for calcified coronary lesions—boosting FDA prospects, investor confidence, and market potential.

Boston Scientific’s May 2026 moves: a $2 billion share‑repurchase boost EPS slightly, while a $1.5 billion stake in MiRus aims to capture growth in the high‑margin TAVR market.

Boston Scientific’s latest clinical data on FARAPULSE, WATCHMAN, and EMBLEM shows higher success and lower risk, boosting reimbursement prospects and market share in cardiac devices.